Claudia J Posso-De Los Rios1, Enas Tadros1, Richard C Summerbell2,3,4, James A Scott2,3,4. 1. Dermatology Clinic, DermCare. 1065 Canadian Pl Unit 206, Mississauga, ON, Canada. 2. 7938274071 Dalla Lana School of Public Health, University of Toronto, ON, Canada. 3. Dynacare Laboratories. 115 Midair Court, Brampton, ON, Canada. 4. Sporometrics, 219 Dufferin Street, Suite 20C, Toronto, ON, Canada.
Abstract
BACKGROUND: Trichophyton mentagrophytes type VIII (segregated as Trichophyton indotineae) is a new strain of antifungal resistant Trichophyton spp. that has been found in different countries around the world. This new strain has been found to be resistant to terbinafine. OBJECTIVES: We present the clinical characteristics, diagnosis and treatment approach of Canadian patients with mycology and molecular confirmation of superficial mycosis caused by T. indotineae. METHODS: Mycology testing from cultures and PCR were used to confirm T. indotineae. We collected clinical information from patients with a confirmed diagnosis. RESULTS: We report eight Canadian patients mainly presenting with extensive superficial mycosis due to T. indotineae. Three patients presented lesions on the face in addition to lesions on their body. Four patients were initially started on itraconazole or fluconazole, one patient was started on topical therapy, and three patients were referred to infectious disease. CONCLUSIONS: This new strain represents a dermatology and public health concern. Treatment guidelines are lacking. We include a practical approach and treatment recommendations for clinicians who will be encountering these emerging cases in Canada while waiting for evidence-based treatment guidelines.
BACKGROUND: Trichophyton mentagrophytes type VIII (segregated as Trichophyton indotineae) is a new strain of antifungal resistant Trichophyton spp. that has been found in different countries around the world. This new strain has been found to be resistant to terbinafine. OBJECTIVES: We present the clinical characteristics, diagnosis and treatment approach of Canadian patients with mycology and molecular confirmation of superficial mycosis caused by T. indotineae. METHODS: Mycology testing from cultures and PCR were used to confirm T. indotineae. We collected clinical information from patients with a confirmed diagnosis. RESULTS: We report eight Canadian patients mainly presenting with extensive superficial mycosis due to T. indotineae. Three patients presented lesions on the face in addition to lesions on their body. Four patients were initially started on itraconazole or fluconazole, one patient was started on topical therapy, and three patients were referred to infectious disease. CONCLUSIONS: This new strain represents a dermatology and public health concern. Treatment guidelines are lacking. We include a practical approach and treatment recommendations for clinicians who will be encountering these emerging cases in Canada while waiting for evidence-based treatment guidelines.
Entities:
Keywords:
Trichophyton indotineae; Trichophyton mentagrophytes type VIII; dermatophyte infection; terbinafine-resistant tinea corporis
Authors: Thi Minh Chau Ngo; Phuong Anh Ton Nu; Chi Cao Le; Thi Ngoc Thuy Ha; Thi Bich Thao Do; Giang Tran Thi Journal: Med Mycol Case Rep Date: 2022-05-13
Authors: Chao Tang; Sarah A Ahmed; Shuwen Deng; Lu Zhang; Jan Zoll; Abdullah M S Al-Hatmi; Jacques F Meis; Rameshwari Thakur; Yingqian Kang; G Sybren de Hoog Journal: Front Microbiol Date: 2022-08-23 Impact factor: 6.064